Lineage Cell Therapeutics, Inc.
LCTX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000876343
In the last 90 days, Lineage Cell Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 132 institutions reported holding it in 13F filings for Q2 2026, worth $153.0M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 17, 2026
- $206.4M
- Insider buysLast 90 days, $17.1K in total
- 1
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +2 vs. previous quarter
- 132
- 13F valueReported value at the end of Q2 2026
- $153.0M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $14.6M
- +53.2% year over year
- Net income, FY2025
- -$63.5M
- No comparable prior period
- Free cash flow, FY2025
- -$19.4M
- No comparable prior period
- Revenue, Q3 FY2026
- $1.43M
- −61.0% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $63.5M (436.5% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 24.3M
- Shares sold short
- Change
- −1.58M
- −6.1% vs. previous
- Days to cover
- 19.27
- At average daily volume
Superinvestors holding LCTX, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding LCTX at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Lineage Cell Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 16, 2026 (view filing)5:00 PM ET | Nov 16 | Same day | Howe Jill AnnChief Financial Officer | PPurchase | +20.0K | $0.855 | +$17.1K | +78.4%45.5K after | |
| Mar 12, 2026 (view filing) | Mar 12 | Same day | Culley Brian MPresident and CEO | PPurchase | +15.0K | $1.63 | +$24.4K | +6.2%255.5K after | |
| Jan 28, 2025 (view filing)7:49 PM ET | Jan 27 | 1 day | Broadwood Partners, L.P. and 2 othersDirector, 10% Owner | PPurchase | +7.89M | $0.76 | +$6.00M | +18.9%49.6M after | |
| Jan 28, 2025 (view filing)7:49 PM ET | Jan 27 | 1 day | Broadwood Partners, L.P. and 2 othersDirector, 10% Owner | PPurchase | 0 | – | $0 | 0.0%49.6M after | |
| Jan 28, 2025 (view filing)7:49 PM ET | Jan 27 | 1 day | Broadwood Partners, L.P. and 2 othersDirector, 10% Owner | PPurchase | +7.89M | $0.00 | $0 | –7.89M after | Derivative |
| Jan 28, 2025 (view filing)7:49 PM ET | Jan 27 | 1 day | Broadwood Partners, L.P. and 2 othersDirector, 10% Owner | PPurchase | +7.89M | $0.00 | $0 | –7.89M after | Derivative |
| Nov 26, 2024 (view filing) | Nov 26 | Same day | Howe Jill AnnChief Financial Officer | PPurchase | +15.0K | $0.59 | +$8.85K | +142.9%25.5K after | |
| Nov 26, 2024 (view filing) | Nov 26 | Same day | Samuel George A. IIIGeneral Counsel | PPurchase | +15.0K | $0.60 | +$9.00K | +208.8%22.2K after | |
| Nov 25, 2024 (view filing) | Nov 22 | 3 days | Mulroy Michael H.Director | PPurchase | +40.0K | $0.57 | +$22.8K | +15.5%298.6K after | |
| Nov 22, 2024 (view filing) | Nov 21 | 1 day | Culley Brian MPresident and CEO | PPurchase | +40.0K | $0.60 | +$24.0K | +25.8%194.8K after |
Top 10 13F holders, Q2 2026
See all 132 holdersThe largest institutional positions in Lineage Cell Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Broadwood Capital Inc | 49,560,992 | $64.9M | 3.39% | 00.0% | Unchanged |
| BlackRock, Inc. | 13,186,895 | $17.3M | 0.00% | +9,322,138+241.2% | Added |
| Vanguard Capital Management LLC | 9,054,918 | $11.9M | 0.00% | +736,233+8.9% | Added |
| Defender Capital, LLC. | 6,598,899 | $8.64M | 2.81% | −130,700−1.9% | Reduced |
| Geode Capital Management, LLC | 5,299,457 | $6.94M | 0.00% | +2,776,343+110.0% | Added |
| Raffles Associates LP | 5,197,788 | $6.81M | 5.80% | −165,000−3.1% | Reduced |
| Fifth Third Bancorp | 4,600,000 | $6.03M | 0.01% | 00.0% | Unchanged |
| Millennium Management LLC | 3,018,567 | $3.95M | 0.00% | −2,542,807−45.7% | Reduced |
| State Street Corp | 2,314,180 | $3.03M | 0.00% | +1,224,069+112.3% | Added |
| Vanguard Fiduciary Trust Co | 1,668,629 | $2.19M | 0.00% | +344,471+26.0% | Added |
Holders of 5% or more of LCTX
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Lineage Cell Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Broadwood Partners, L.P. | 13D/A | 23.10%57.8M shares | −1.40 ppfrom 24.50% | Mar 16, 20216 filings | Nov 14, 2025 | SEC |
| BlackRock, Inc. | 13G | 5.30%13.2M shares | +4.30 ppfrom 1.00% | Oct 22, 20246 filings | Jul 29, 2026 | SEC |
| Chernett Jorey | 13G | 5.00%11.4M shares | New | Sep 26, 20251 filing | Sep 26, 2025 | SEC |